EUCTR2018-002757-30-BE进行中（未招募）1 期
A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa - Efficacy and safety of different investigational drugs for the treatment of hidradenitis suppurativa
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male and female patients, 18 to 65 years of age (inclusive), with clinically diagnosed HS for at least 12 months prior to Screening.
- •- For Cohort A (iscalimab) and C (MAS825): A total of at least 5 inflammatory lesions, i.e., abscesses and/or inflammatory nodules.
- •- For Cohort B (LYS006) and D (LOU064): A total of at least 3 inflammatory lesions, i.e., abscesses and/or inflammatory nodules.
- •- For all Cohorts: No more than 15 fistulae and at least two anatomical areas need to be involved with HS lesions.
- •Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 197
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •1. Use of other investigational drugs at the time of screening, or within 30 days or 5 half-lives of randomization, whichever is longer; or longer if required by local regulations.
- •2. Use/receipt of some specific treatments during specified time frames
- •3. WOCBP, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for the subsequent 14 weeks after the
- •last study drug administration for Cohort A (iscalimab) and the subsequent 2 weeks after the last study drug administration for Cohort B (LYS006) and cohort D (LOU064). In Cohort C (MAS825), WoCBP will be asked to adhere to highly effective contraception from at least 3 months prior to first drug administration and until 5 months after the final dose (Day 225 to Day 253), when a pregnancy test will be conducted.
- •Other protocol-defined exclusion criteria may apply
研究者
相似试验
已完成
2 期
A randomized, subject and investigator blinded, placebo-controlled, multicenter study in parallel groups to assess the efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne10040790AcneNL-OMON50746ovartis8
进行中（未招募）
1 期
A study to assess if CMK389 is effective, safe and tolerable in patients with moderate to severe Atopic Dermatitis (AD)EUCTR2020-003406-31-ESovartis Farmacéutica, S.A.64
进行中（未招募）
1 期
A study to assess if CMK389 is effective, safe and tolerable in patients with moderate to severe Atopic Dermatitis (AD)Moderate to Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-003406-31-HUovartis Pharma AG64
进行中（未招募）
1 期
A safety and efficacy study to learn how well JM112 works in patients with moderate to severe inflammatory acne.Moderate to Severe Inflammatory AcneMedDRA version: 19.1Level: LLTClassification code 10000519Term: Acne vulgarisSystem Organ Class: 100000004858EUCTR2016-002492-95-DEovartis Pharma AG75
进行中（未招募）
1 期
A safety and efficacy study to learn how well JM112 works in patients with moderate to severe inflammatory acne.Moderate to Severe Inflammatory AcneMedDRA version: 19.1 Level: LLT Classification code 10000519 Term: Acne vulgaris System Organ Class: 100000004858EUCTR2016-002492-95-NLovartis Pharma AG52